三阴性乳腺癌症中泌乳素受体表达与淋巴结转移的关系

IF 0.4 Q4 ONCOLOGY

Breast Cancer Management Pub Date : 2022-12-01 DOI:10.2217/bmt-2022-0006

Mahdiss Mohamadianamiri, A. Ebrahimi, F. Farzaneh, Majid Aklami, Mina Momeni, Tannaz Hajighasem, Hossein Shirazi, Mohammadreza Zeinadini

{"title":"三阴性乳腺癌症中泌乳素受体表达与淋巴结转移的关系","authors":"Mahdiss Mohamadianamiri, A. Ebrahimi, F. Farzaneh, Majid Aklami, Mina Momeni, Tannaz Hajighasem, Hossein Shirazi, Mohammadreza Zeinadini","doi":"10.2217/bmt-2022-0006","DOIUrl":null,"url":null,"abstract":"Background: Triple-negative breast cancer (TNBC) is associated with a poor prognosis and requires more aggressive treatment. Aim: The study aimed to evaluate the prophetic role of the prolactin receptor (PRLR) in TNBC stratification. Materials & methods: In a retrospective study, 58 formalin-fixed paraffin-embedded tumor tissues from patients diagnosed with TNBC were examined for PRLR expression using immunohistochemistry. The potential associations between PRLR expression and tumor characteristics were assessed. Result: PRLR expression was negative in 36 (62%) patients and positive in 22 (38%) patients. The number of positive PRLR tumors was significantly higher in patients without lymph node involvement (p = 0.019). Conclusion: PRLR expression was negatively associated with lymph node invasion in TNBC.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":"1 1","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The association between expression of prolactin receptor and lymph node involvement in triple-negative breast cancer\",\"authors\":\"Mahdiss Mohamadianamiri, A. Ebrahimi, F. Farzaneh, Majid Aklami, Mina Momeni, Tannaz Hajighasem, Hossein Shirazi, Mohammadreza Zeinadini\",\"doi\":\"10.2217/bmt-2022-0006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Triple-negative breast cancer (TNBC) is associated with a poor prognosis and requires more aggressive treatment. Aim: The study aimed to evaluate the prophetic role of the prolactin receptor (PRLR) in TNBC stratification. Materials & methods: In a retrospective study, 58 formalin-fixed paraffin-embedded tumor tissues from patients diagnosed with TNBC were examined for PRLR expression using immunohistochemistry. The potential associations between PRLR expression and tumor characteristics were assessed. Result: PRLR expression was negative in 36 (62%) patients and positive in 22 (38%) patients. The number of positive PRLR tumors was significantly higher in patients without lymph node involvement (p = 0.019). Conclusion: PRLR expression was negatively associated with lymph node invasion in TNBC.\",\"PeriodicalId\":43086,\"journal\":{\"name\":\"Breast Cancer Management\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/bmt-2022-0006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/bmt-2022-0006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：癌症三阴性与预后不良相关，需要更积极的治疗。目的：本研究旨在评估泌乳素受体（PRLR）在TNBC分层中的预测作用。材料与方法：在一项回顾性研究中，用免疫组织化学方法检测58例TNBC患者福尔马林固定石蜡包埋的肿瘤组织中PRLR的表达。评估了PRLR表达与肿瘤特征之间的潜在相关性。结果：PRLR表达阴性36例（62%），阳性22例（38%）。无淋巴结转移的患者中PRLR阳性肿瘤的数量显著增加（p=0.019）。结论：TNBC中PRLR的表达与淋巴结转移呈负相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The association between expression of prolactin receptor and lymph node involvement in triple-negative breast cancer

Background: Triple-negative breast cancer (TNBC) is associated with a poor prognosis and requires more aggressive treatment. Aim: The study aimed to evaluate the prophetic role of the prolactin receptor (PRLR) in TNBC stratification. Materials & methods: In a retrospective study, 58 formalin-fixed paraffin-embedded tumor tissues from patients diagnosed with TNBC were examined for PRLR expression using immunohistochemistry. The potential associations between PRLR expression and tumor characteristics were assessed. Result: PRLR expression was negative in 36 (62%) patients and positive in 22 (38%) patients. The number of positive PRLR tumors was significantly higher in patients without lymph node involvement (p = 0.019). Conclusion: PRLR expression was negatively associated with lymph node invasion in TNBC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Breast Cancer Management ONCOLOGY-

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Breast Cancer Management (ISSN: 1758-1923) addresses key issues in disease management by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Breast Cancer Management provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances clinical practice in the field are reported and analyzed by international experts. The journal presents this information in clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. Coverage includes: Diagnosis and imaging, Surgical approaches, Radiotherapy, Systemic therapies, Cancer clinical trials, Genetic aspects of disease, Personalized medicine, Translational research and biomarker studies, Management of psychological distress, Epidemiological studies, Pharmacoeconomics, Evidence-based treatment guidelines.